Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation

Inclusion Criteria:

* Female and/or male aged ≥ 18 years.
* Histologically confirmed diagnosis of stage III NSCLC, planned for treatment with concurrent chemoradiation and consolidation immune checkpoint inhibitor as per standard of care with no medical contraindications to therapy.
* Patients with ECOG performance status 0-2 within 4 weeks of randomization.
* Adequate liver function (no evidence of Child-Pugh class C disease or cirrhosis) as per blood work done within 30 days of registration.
* Adequate kidney function (Creatinine clearance \> 50 mL/min) as per blood work done within 30 days of registration.

Exclusion Criteria:

* Participation in another clinical study with an investigational product during the last 6 months prior to registration.
* Patients who will have surgery as part of curative treatment.
* Previous radiotherapy to intended treatment volumes in the thorax.
* Active pregnancy.
* Life expectancy of less than 12 months.
* Hypersensitivity to Pentoxifylline or other xanthines such as caffeine, theophylline and theobromine or tocopherol (vitamin E).
* Participant has a history of acute (within 3 months) myocardial infarction, coronary artery disease, or cardiac arrhythmias.
* Ongoing hemorrhage or major bleeding risk. Patients on antiplatelets agents and anticoagulants (Aspirin, Clopidogrel, Ticlopidine, Cilostazol, Dipyridamole, Heparin, Dalteparin, Enoxaparin and Warfarin) can be enrolled, but major bleeding events will be captured. Patients on Warfarin will need frequent monitoring of their coagulation time to adjust Warfarin dosage.